Please select the eligibility criteria that correspond to the clinical trial below.
Title: Sublingual Versus Vaginal Misoprostol In Medical Treatment of First Trimestric Missed Miscarriage: A Randomized Controlled Trial.
Brief Summary: The aim of this work is to compare the effectiveness of vaginal versus sub-lingual misoprostol for medical treatment of first trimester missed miscarriage.


Options:
A: Inclusion Criteria:

Early pregnancy failure, 6-14 weeks postmenstrual with

* a crown-rump length ≥ 6mm and no cardiac activity OR
* a crown-rump length \<6mm and no fetal growth at least one week later OR
* a gestational sac with absent embryonic pole for at least one week.

  * At least one week after diagnosis OR a discrepancy of at least one week between crown-rump length and calendar gestational age
  * Intra-uterine pregnancy
  * Women aged above 16 years
  * Hemodynamic stable patient
  * No signs of infection
  * No signs of incomplete abortion
  * No contraindications for mifepristone or misoprostol

Exclusion Criteria:

* Patient does not meet inclusion criteria, discovered after randomization
* Inability to give informed consent
* Known clotting disorder or use of anticoagulants
* Known risk factors for, or presence of, a cardiovascular disease
* Language barrier
B: Inclusion Criteria:

* Gestational age \< 63 days by LMP, ultrasound or clinical assessment.
* General good health including absence of conditions which contraindicate the use of mifepristone and misoprostol for pregnancy termination.
* Agrees to return for follow-up visit and willing to provide an address and/or telephone number for purposes of follow-up.
* Able to consent to study participation.

Exclusion Criteria:

* Gestational age \> 63 days
* Confirmed or suspected ectopic or molar pregnancy
* Contraindications to medical abortion including IUD in place (must be removed before procedure), chronic adrenal failure, concurrent long-term corticosteroid therapy, history of allergy to mifepristone, misoprostol or prostaglandin, hemorrhagic disorders or concurrent anticoagulant therapy, inherited porphyries.
C: Inclusion Criteria:

* Before randomization: Gestational age not more than 63 days as estimated by last menstrual period (LMP).
* After randomization: Gestational age not more than 63 days as estimated by abdominal and bimanual pelvic examination.
* Above national age of consent
* Willing to return to the clinic for misoprostol on Day 3 and for a follow-up visit on Day 10 to 14.
* Residence within the geographical area specified for each clinic and no more than one hour from emergency referral services.
* Willing to provide written informed consent to participate in the study and to be randomly assigned to a provider team.
* Able to understand the nature of the study, advice and instructions given by health providers.

Exclusion Criteria:

* Previous allergic reaction to one of the drugs in the medical abortion regimen
* Known or suspected ectopic pregnancy or undiagnosed adnexal mass
* Inherited porphyria (rare genetic blood diseases)
* Chronic adrenal failure
* Long term corticosteroid therapy
* Haemorrhagic disorder or anticoagulant therapy (blood thinner medications)
* IUD in utero that can not be removed before taking mifepristone
* Previous enrolment in the study (i.e. no repeat abortions; only one abortion per woman in the study)
* Unwilling or unable to return to clinic for follow-up visit.
D: Inclusion Criteria:

* All women above 18 years of age
* Less than 12 weeks of gestation.
* Pregnancy is confirmed by pregnancy test or ultrasound scan.
* missed abortion
* Normal general and gynecological examination.
* The size of the uterus on pelvic examination was compatible with the estimated duration of pregnancy

Exclusion Criteria:

* Hemodynamically unstable.
* Suspected sepsis with temperature 38 °C.
* Concurrent medical illness e.g. hematological, cardiovascular, thromboembolism, respiratory illnesses, recent liver disease or pruritus of pregnancy.
* Presence of intrauterine contraceptive device (IUCD).
* Suspect or proven ectopic pregnancy.
* Failed medical or surgical evacuation before presentation.
* Known allergy to misoprostol.

Answer: D